Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer's & Dementia - Tập 7 Số 3 - Trang 280-292 - 2011
Reisa A. Sperling1, Paul M. Thompson2, Laurel Beckett3, David A. Bennett4, Suzanne Craft5,6, Anne M. Fagan7, Takeshi Iwatsubo8, Clifford R. Jack9, Jeffrey Kaye10, Thomas S. Wingo11, Denise C. Park12, Eric M. Reiman13, Christopher C. Rowe14, Eric Siemers15, Yaakov Stern16, Kristine Yaffe17, María C. Carrillo18, Bill Thies18, Marcelle Morrison‐Bogorad19, Molly V. Wagster19, Creighton H. Phelps19
1Department of Neurology Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School Boston MA USA
2Department of Neurosciences, University of California San Diego, San Diego, CA, USA
3Division of Biostatistics, School of Medicine, University of California, Davis, CA, USA
4Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago IL, USA
5Department of Psychiatry and Behavioral Sciences Geriatric Research, Education, and Clinical Center, Veterans Affairs Puget Sound; University of Washington School of Medicine Seattle WA USA
6University of Washington School of MedicineSeattleWAUSA
7Department of Neurology, Washington University School of Medicine, St. Louis, Mo. USA
8Department of Neuropathology Graduate School of Medicine, University of Tokyo Tokyo Japan
9Department of Radiology Mayo Clinic Minnesota Rochester MN USA
10Departments of Neurology and Biomedical Engineering Layton Aging & Alzheimer's Disease Center, Oregon Center for Aging & Technology, Oregon Health & Science University and Portland Veteran's Affairs Medical Center Portland OR USA
11Department of Pathology, University of Washington, Seattle, WA USA
12Center for Vital Longevity, University of Texas at Dallas, Dallas, TX, USA
13Banner Alzheimer's Institute, Phoenix, AZ, USA
14Austin Health, University of Melbourne, Melbourne, Australia
15Eli Lilly and Company, Indianapolis, IN, USA
16Cognitive Neuroscience Division Taub Institute, Columbia University College of Physicians and Surgeons New York NY USA
17Departments of Psychiatry, Neurology, and Epidemiology and Biostatistics University of California San Francisco, San Francisco VA Medical Center San Francisco CA USA
18Alzheimer's Association Chicago IL USA
19Division of Neuroscience, National Institute on Aging, Bethesda, MD, USA

Tóm tắt

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.

Từ khóa


Tài liệu tham khảo

10.1097/01.wad.0000184005.22611.cc

10.1016/S1474-4422(10)70223-4

10.1016/j.jalz.2011.03.004

10.1016/j.jalz.2011.03.008

10.1016/j.jalz.2011.03.005

10.1523/JNEUROSCI.4305-10.2010

10.1523/JNEUROSCI.4521-10.2010

10.1126/science.1197623

10.1126/science.1074069

10.1196/annals.1297.001

10.1038/nm1782

10.1212/WNL.0b013e3181a92c36

10.1001/archneur.61.5.661

10.1001/archneurol.2009.27

10.1001/archpsyc.63.2.153

10.1159/000095761

10.1097/01.JGP.0000235689.42910.0d

10.1212/01.wnl.0000271087.67782.cb

10.1016/j.neuropsychologia.2009.03.004

10.1001/archneurol.2007.27

10.1212/WNL.0b013e3181f25b5e

10.1016/S1474-4422(09)70299-6

10.1073/pnas.2635903100

Filippini N, 2003, Distinct patterns of brain activity in young carriers of the APOE‐epsilon4 allele, Proc Natl Acad Sci U S A, 106, 7209, 10.1073/pnas.0811879106

10.1523/JNEUROSCI.3987-10.2010

10.1212/WNL.0b013e3181e7ca82

10.1016/j.neurobiolaging.2010.04.007

10.1212/01.wnl.0000228230.26044.a4

Jack CR, 2008, 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment, Brain, 131, 665, 10.1093/brain/awm336

10.1212/01.wnl.0000326146.60732.d6

10.1001/archneurol.2010.179

10.1007/s12017-010-8126-6

10.1212/WNL.42.9.1681

10.1212/WNL.46.3.707

10.1212/01.wnl.0000219668.47116.e6

10.2105/AJPH.88.9.1337

10.1016/j.jalz.2009.03.001

10.1212/01.wnl.0000171397.32851.bc

10.1523/JNEUROSCI.0730-07.2007

10.1212/01.wnl.0000303973.71803.81

10.1073/pnas.0900345106

10.1016/j.neuron.2009.07.003

10.1523/JNEUROSCI.3189-09.2009

10.1016/j.biopsych.2009.08.024

10.1093/cercor/bhp279

10.1093/cercor/bhn113

10.1371/journal.pone.0012853

JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)

10.1016/j.neuroimage.2010.10.027

Pike KE, 2007, Beta‐amyloid imaging and memory in non‐demented individuals: evidence for preclinical Alzheimer's disease, Brain, 130, 2837, 10.1093/brain/awm238

10.1093/brain/awn320

10.1001/archneur.65.11.1509

10.1002/ana.21904

10.1002/ana.22248

JMSchott JWBartlett NCFox JBarnes;Investigators ftAsDNI. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42.Ann Neurol 2011 (in press).

10.1001/archneur.64.3.noc60123

10.1212/01.wnl.0000267428.62582.aa

10.1001/archneurol.2009.272

10.1212/WNL.0b013e3181d3e3e9

10.1001/archneurol.2009.269

10.1016/j.neuropsychologia.2008.02.008

10.1093/brain/awq383

10.1212/WNL.0b013e3181af79fb

10.1001/jama.2010.1995

10.1017/S1355617708080375

10.1002/ana.21610

10.1002/ana.20730

10.1007/BF00308809

10.1001/jama.1995.03520410048025

10.1212/WNL.54.5.1109

10.1001/archneur.59.11.1737